Clinical Trial Update: BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating BIVV020 (SAR445088) for preventing and treating antibody-mediated rejection in transplant recipients is currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transplant Rejection

Drugs mentioned

• BIVV020

Snippet

Sponsor: Sanofi | Conditions: Transplant Rejection | Phase 2 | Status: ACTIVE_NOT_RECRUITING